Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia

Study ID	NCT00178607
Status	Recruiting
Phase	-
Source	ClinicalTrials.gov

Started	Aug 1 2002
Last Updated	Jul 10 2009
Estimated Completion	Jul 10 2009

About this clinical study

Summary

To correlate the HLA type and genetic defect with hemophilia A.

Condition / Disease

Hemophilia A

Description

One of the most serious complications of treatment in patients with hemophilia A or hemophilia B is the development of an inhibitor, which is an antibody that neutralizes the factor VIII or IX coagulant activity. Up to one fourth of patients with severe hemophilia A develop an inhibitor but at present it is not possible to predict which patients will develop such antibody. The ability to predict an inhibitor development at an individual level would greatly improve therapeutic approach to this serious problem

Overview

Gender	male

Target Enrollment	150

Recruiting Healthy Volunteers	No

Locations

The Univeristy of Texas Health Science Center at Houston

Houston

4 mi

Criteria

Inclusion Criteria:

Severe Hemophilia A with an inhibitor level of 0.6 B.U. or higher

Exclusion Criteria:

Severe Hemophilia A with a negative inhibitor

Contact

Overall Contact

Madeline Cantini, BSN - 713-500-8377

Investigators

Miguel Escobar, MD	Principal Investigator

Similar Clinical Trials near Houston, TX

Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Unilateral Knee Replacement

Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease

Rituximab to Treat Severe Hemophilia A

Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B

Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A

Home